ILLUMINA, INC. 8-K

What Happened
Illumina announced on January 30, 2026 that it completed the previously disclosed acquisition of Standard BioTools’ aptamer-based and functional proteomics business (including SomaLogic and Sengenics entities). The purchase price was $350,000,000 in cash (subject to customary adjustments). The acquisition was governed by a Stock Purchase Agreement dated June 22, 2025.

Key Details

• Acquisition closing date: January 30, 2026; Purchase Agreement dated June 22, 2025.
• Cash purchase price: $350,000,000, subject to customary post-closing adjustments.
• Additional payments: royalty streams on certain product/service revenues and up to $75,000,000 in potential milestone payments to Standard BioTools.
• Scope: includes aptamer-based/functional proteomics assets (KREX, Single SOMAmer, translational & diagnostic assays); excludes Standard BioTools’ mass cytometry and microfluidics businesses.

Why It Matters
This deal expands Illumina’s capabilities in proteomics by adding aptamer-based technologies and related assays, potentially broadening its product portfolio and revenue streams (including royalties and milestone payments). The filing also highlights customary integration and execution risks and includes forward-looking cautionary language—investors should note integration, commercialization, manufacturing, and market adoption risks described in Illumina’s public filings.